Unspecified tumor-associated antigens on solid tumor cells (TAA)

Unspecified tumor-associated antigens on solid tumor cells represent a diverse group of molecules, including proteins, glycoproteins, and glycolipids, that are overexpressed or aberrantly expressed by malignant cells in solid tumors (National Cancer Institute, 2023). Unlike tumor-specific antigens, these may also be present in lower quantities on normal cells, but their relative abundance on tumor cells makes them viable targets for immunotherapy (Vigneron, 2015). The term "unspecified" is frequently used in the context of polyvalent vaccines or autologous cell therapies, such as Gemogenovatucel-T or Belagenpumatucel-L, which utilize the full antigenic profile of a patient's tumor to stimulate a broad immune response (Senzer et al., 2012). This approach is designed to address the inherent heterogeneity of solid tumors and reduce the likelihood of immune escape through antigen loss (Abbas et al., 2014). By targeting a wide array of antigens simultaneously, these therapies aim to activate both CD4+ and CD8+ T-cells to recognize and eliminate cancerous tissue throughout the body. These antigens can include differentiation antigens, overexpressed self-antigens, or products of mutated genes, and their clinical application often involves the use of whole-cell lysates to act as an "in situ" vaccine (Pardoll, 2012). This strategy is particularly relevant for solid tumors where a single dominant driver antigen has not been identified, allowing for a personalized treatment approach that adapts to the unique molecular signature of an individual's malignancy.

Other names

Tumor-associated antigensSolid tumor antigensCancer-associated antigensNeoantigensPolyvalent tumor antigens

Induction of a polyvalent immune response through the presentation of a broad spectrum of tumor-derived antigens to the host immune system, typically involving the activation of T-cells by professional antigen-presenting cells.